СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О ПРОТИВООПУХОЛЕВОМ ИММУНИТЕТЕ
https://doi.org/10.17650/1726-9784-2015-14-3-19-28
Аннотация
Об авторах
Ирина Жановна ШубинаРоссия
А. В. Сергеев
Россия
Л. Т. Мамедова
Россия
Н. Ю. Соколов
Россия
М. В. Киселевский
Россия
Список литературы
1. Барышников, А.Ю. Взаимоотношение опухоли и иммунной системы организма // Практическая онкология. - 2003. - Т.4, №3. - С.127-30.
2. Кадагидзе З.Г. NKT-клетки и противоопухолевый эффект // Российский биотерапевтический журнал. - 2011. - Т.10, №3. - С. 9-15.
3. Шубина И.Ж., Чикилева И.О., Михайлова И.Н. и др. Активированные натуральные киллеры в клеточной иммунотерапии // Российский иммунологический журнал. - 2012. - Т. 6(15), № 1. - С. 71-9.
4. Alshaker H.A., Matalka K.Z. IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors // Cancer Cell Int. - 2011. - 23(11). - P. 33-44.
5. Asselin-Paturel C., Trinchieri G. Production of type I interferons: plasmacytoid dendritic cells and beyond // J Exp Med. - 2005. - 202. - Р. 461-5.
6. Booy S., Hofland L., van Eijck C. Potentials of interferon therapy in the treatment of pancreatic cancer // J Interferon Cytokine Res. - 2015. - 35(5). - Р. 327-339.
7. Boyton R.J., Altmann D.M. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease // Clinical and Experimental Immunology. - 2007. - 149. - P. 1-8.
8. Burnet M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications // Br Med J. - 1957. - №1(5023). - Р.841-7.
9. Camus M., Tosolini M., Mlecnik B. et al. Coordination of intratumoral immune reaction and human colorectal cancer recurrence //Cancer Res. - 2009. - 69. - Р. 2685-93.
10. Cheever M., Allison J.P., Ferris A.S. et al. The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research //Clin Cancer Res. - 2009. - 15. - Р. 5323-37.
11. Coronella J.A., Spier C., Welch M. et al. Antigen driven oligoclonal expansion of tumor-infiltrating В cells in infiltrating ductal carcinoma of the breast //J Immunol. - 2002. - 169. - Р. 1829-36.
12. Diebold S.S. Determination of T-cell fate by dendritic cells // Immunol Cell Biol. - 2008. - 86. - Р. 389-97.
13. Dighe A.S., Richards E., Old L.J., Schreiber R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors //Immunity. - 1994. - №1. - Р. 447-56.
14. Dunn G.P., Bruce A.T., Ikeda H. et al. Cancer immunoediting: from immunosurveillance to tumor escape //Nat Immunol. - 2002. - №3. - Р. 991-8.
15. Dunn G.P., Koebel C.M., Schreiber R.D. Interferons, immunity and cancer immunoediting // Nat Rev Immunol. - 2006. - 6. - Р. 836-48.
16. Ehrlich P. Ueber den jetzigen Stand der Karzinomforschung //Ned Tijdschr Geneeskd. - 1909. - №5. - Р. 273-90.
17. Ferris R.L., Whiteside T.L., Ferrone S. Immune escape associated with functional defects in antigen processing machinery in head and neck cancer //Clin Cancer Res. - 2006. - № 12. - Р. 3890-5.
18. Ferrone S., Whiteside T.L. Tumor microenvironment and immune escape //Surg Oncol Clin North Am. - 2007. - № 16. - Р. 755-74.
19. Finn O.J., Binder R.J., Brickner A.G. et al. Human tumor antigens as targets of immunosurveillance and candidates for cancer vaccines. In: Gires O. Seliger В., editors. Tumor-associated antigens: identification, characterization, and clinical applications. Weinheim (Germany): Wiley-VCH, 2009. - Р. 23-43.
20. Gresser I., Maury C., Vignaux F. et al. Antibody to mouse interferon alpha/beta abrogates resistance to the multiplication of Friend erythroleukemia cells in the livers of allogeneic mice // J Exp Med. - 1988. - 168. -Р. 1271-91.
21. Gumperz J.E. CD1d-restricted “NKT” cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses? // Journal of Leukocyte Biology. - 2004. - 76. - P. 307-14.
22. Hailemichael Y., Overwijk W.W. Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination // Int J Biochem Cell Biol. - 2014. - 53. - Р. 46-50.
23. Jager E., Karbach J., Gnjatic S. et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NYESO- 1-specific immune responses in cancer patients // Proc Natl Acad Sci USA. - 2006. - 103. - Р. 14453-8.
24. Jewett A., Tseng H.C. Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells // J Cancer. - 2011. - №2. - Р. 443-57.
25. June C.H. Adoptive T cell therapy for cancer in the clinic // J Clin Invest. - 2007. - 117. - Р. 1466-76.
26. Kim R., Emi M., Tanabe K. Cancer immunoediting from immune surveillance to immune escape // Immunology. - 2007. - 1. - P. 1-14.
27. Klein G. Tumor antigens //annu rev microbiol. - 1966. - 20. - Р. 223-52.
28. Kryczek I., Banerjee M., Cheng P. et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor microenvironment // Blood. - 2009. - 114. - Р. 1141-9.
29. Lanier L.L. Natural killer cell receptor signaling // Curr Opin Immunol. - 2003. - 15. - Р. 308-14.
30. Luszynski W., Krawczuk-Rybak M., Stasiak-Barmuta A. Myeloid-derived suppressor cells - the new mechanism of immunosuppression in cancer // Postepy Hig Med Dosw. - 2008. - 21(62). - Р. 18-22.
31. Mandapathil M., Szczepanski M.J., Szajnik M. et al. Increased ectonucleotidase expression and activity in Treg of patients with head and neck cancer //Clin Cancer Res. - 2009. - 15. - Р. 6348-57.
32. Manjili M.H. Revisiting cancer immunoediting by understanding cancer immune complexity // J Pathol. - 2011. - 224(1). - P. 5-9.
33. Martinez O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization // Front Biosci. - 2008. - 13. - Р. 453-61.
34. Obeid M., Panaretakis T., Tesniere A. et al. Leveraging the Immune System during Chemotherapy: Moving Calreticulin to the Cell Surface Converts Apoptotic Death from ‘‘Silent’’ to Immunogenic // Cancer Res. - 2007. - 67(17). - P. 7941-5.
35. Oble D.A., Loewe R., Yu P., Mihm M.C. Jr. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma // Cancer Immun. - 2009. - 9. - Р. 3-23.
36. Ochoa A.C., Zea A.H., Hernandez C., Rodri'guez P.C. Arginase, prostaglandins, and myeloid supressor cells in renal cell carcinoma // Clin Cancer Res. - 2007. - 13. - Р. 721-6s.
37. Onji M., Akbar Sk.Md. On dendritic cell-based therapy for cancers // J Zhejiang Univ SCI. - 2005. - 6B(1). - P. 1-3.
38. Parmiani G., De Filippo A., Novellino L., Castelli C. Unique human tumor antigens: immunobiology and use in clinical trials // J Immunol. - 2007. - 178. - Р. 1975-9.
39. Pellegrini M., Mak T. W., Ohashi P.S. Fighting cancers from within: augmenting tumor immunity with cyto kine therapy // Trends Pharmacol Sci. - 2010. - 31(8). - P. 356-63.
40. Provinciali M. Immunosenescence and cancer vaccines // Cancer Immunol Immunother. - 2009. - 58. - Р. 1959-67.
41. Reichert T.E., Strauss L., Wagner E.M. et al. Signaling abnormalities and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma // Clin Cancer Res. - 2002. - № 8. -Р. 3137-45.
42. Romero P., Cerottini J.C., Speiser D.E. The human T cell response to melanoma antigens // Adv Immunol. - 2006. - 92. - Р. 187-224.
43. Schmieder A., Michel J., Schцnhaar K. et al. Differentiation and gene expression profile of tumor-associated macrophages // Semin Cancer Biol. - 2012. - 22(4). - P. 289-97.
44. Seliger B., Quandt D. The expression, function, and clinical relevance of B7 family members in cancer // Cancer Immunol Immunother. - 2012. - 61(8). - Р. 1327-41.
45. Sethi G., Shanmugam M.K., Ramachandran L. et al. Multifaceted link between cancer and inflammation // Biosci Rep. - 2012. - 32(1). - P. 1-15.
46. Shurin G.V., Shurin M.R., Bykovskaja S. et al. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function // Cancer Res. - 2001. - 61. - Р. 363-9.
47. Slavin S.A., Ackerstein R. Or, Shapira M.Y. et al. Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study // Cancer Immunol Immunother. - 2010. - 59. - P. 1511-9.
48. Smyth M.J., Dunn G.P., Schreiber R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity // Adv Immunol. - 2006. - 90. -Р. 1-50.
49. Smyth M.J., Thia K. Y., Street S.E. et al. Differential tumor surveillance by natural killer (NK) and NKT cells // J Exp Med. - 2000. - 191. - Р. 661-8.
50. Storkus W.J., Falo Jr L.D. A ‘good death’ for tumor immunology // Nature Medicine. - 2007. - 13(1). - P. 28-31.
51. Strauss L., Bergmann C., Szczepanski M. et al. A unique subset of CD4/CD25high/FOXP3 T cells secreting IL-10 and TGFb1 mediates suppression in the tumor microenvironment // Clin Cancer Res. - 2007. - 13. -Р. 4345-54.
52. Tan G.X., Zhang H., Feng H. et al. The Therapeutic Effect of Cytokine-Induced Killer Cells on Pancreatic Cancer Enhanced by Dendritic Cells Pulsed with K-RasMutant Peptide // Clinical and Developmental Immunology. - 2011. - 1. - P. 1-9.
53. Thakur A., Littrup P., Paul E.N. et al. Induction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: a pilot study // J Immunother. - 2011. - 34(5). - P. 457-467.
54. Turcotte S., Rosenberg S.A. Immunotherapy for metastatic solid cancers // Adv Surg. - 2011. - 45. - P. 341-60.
55. Vendramini-Costa D.B., Carvalho J.E. Molecular link mechanisms between inflammation and cancer // Curr Pharm Des. - 2012. - 18(26). - Р. 3831-52.
56. Whiteside T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic interventions // Semin Cancer Biol. - 2006. - 16. - Р. 3-15.
57. Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth // Oncogene. - 2008. - 27. - Р. 5904-12.
58. Yang S., Gattinoni L., Liu F. et al. In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells // Cancer Immunol Immunother. - 2011. - 60(5). - P. 739-49.
Рецензия
Для цитирования:
Шубина И.Ж., Сергеев А.В., Мамедова Л.Т., Соколов Н.Ю., Киселевский М.В. СОВРЕМЕННЫЕ ПРЕДСТАВЛЕНИЯ О ПРОТИВООПУХОЛЕВОМ ИММУНИТЕТЕ. Российский биотерапевтический журнал. 2015;14(3):19-28. https://doi.org/10.17650/1726-9784-2015-14-3-19-28
For citation:
Shubina I.Zh., Sergeev A.V., Mamedova L.T., Sokolov N.Yu., Kiselevsky M.V. CURRENT UNDERSTANDING OF ANTITUMOR IMMUNITY. Russian Journal of Biotherapy. 2015;14(3):19-28. (In Russ.) https://doi.org/10.17650/1726-9784-2015-14-3-19-28